Mutational landscape and clonal architecture in grade II and III gliomas

Nature Genetics

Volumn 47, Issue 5, 2015, Pages 458-468

  Suzuki, Hiromichi ^a,b   Aoki, Kosuke ^a,b   Chiba, Kenichi ^c   Sato, Yusuke ^b   Shiozawa, Yusuke ^b   Shiraishi, Yuichi ^c   Shimamura, Teppei ^a   Niida, Atsushi ^c   Motomura, Kazuya ^a   Ohka, Fumiharu ^a,d   Yamamoto, Takashi ^a   Tanahashi, Kuniaki ^a   Ranjit, Melissa ^a   Wakabayashi, Toshihiko ^a   Yoshizato, Tetsuichi ^b   Kataoka, Keisuke ^b   Yoshida, Kenichi ^b   Nagata, Yasunobu ^b   Sato Otsubo, Aiko ^b   Tanaka, Hiroko ^c   Sanada, Masashi ^b   Kondo, Yutaka ^d   Nakamura, Hideo ^e   Mizoguchi, Masahiro ^f   Abe, Tatsuya ^g   Muragaki, Yoshihiro ^h   Watanabe, Reiko ⁱ   Ito, Ichiro ⁱ   Miyano, Satoru ^c   Natsume, Atsushi ^a   Ogawa, Seishi ^b   more..

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^e KUMAMOTO UNIVERSITY   (Japan)

^f KYUSHU UNIVERSITY   (Japan)

^g OITA UNIVERSITY   (Japan)

^h TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

ⁱ SHIZUOKA CANCER CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ISOCITRATE DEHYDROGENASE;

ALLELE; ARTICLE; ASTROCYTOMA; BRAIN SURGERY; CANCER GRADING; CANCER PATIENT; CANCER RECURRENCE; CANCER SURGERY; CLONAL EVOLUTION; CONTROLLED STUDY; COPY NUMBER VARIATION; CORRELATIONAL STUDY; CYTOARCHITECTURE; GENE EXPRESSION; GENE IDENTIFICATION; GLIOBLASTOMA; GLIOMA; HIGH THROUGHPUT SEQUENCING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTIPLE CANCER; OVERALL SURVIVAL; PILOCYTIC ASTROCYTOMA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SOMATIC MUTATION; TUMOR GROWTH; TUMOR LOCALIZATION; BRAIN TUMOR; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETICS; KAPLAN MEIER METHOD; MORTALITY; MUTATION;

BRAIN NEOPLASMS; DNA COPY NUMBER VARIATIONS; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GLIOMA; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; KAPLAN-MEIER ESTIMATE; MUTATION; NEOPLASM GRADING;

EID: 84929129626     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng.3273     Document Type: Article

References (65)

1. Ostrom, Q.T. et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. Neuro-oncol. 15 (suppl. 2), ii1-ii56 (2013
2. Claus, E.B. & Black, P.M. Survival rates and patterns of care for patients diagnosed with supratentorial low-grade gliomas: data from the SEER program, 1973-2001. Cancer 106, 1358-1363 (2006
3. Louis, D.N. et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 114, 97-109 (2007
4. Stupp, R. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987-996 (2005
5. Stupp, R. et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10, 459-466 (2009
6. Bauman, G., Fisher, B., Watling, C., Cairncross, J.G. & Macdonald, D. Adult supratentorial low-grade glioma: long-term experience at a single institution. Int. J. Radiat. Oncol. Biol. Phys. 75, 1401-1407 (2009
7. Smith, J.S. et al. Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J. Clin. Oncol. 26, 1338-1345 (2008
8. Omuro, A. & DeAngelis, L.M. Glioblastoma and other malignant gliomas: a clinical review. J. Am. Med. Assoc. 310, 1842-1850 (2013
9. Johnson, B.E. et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science 343, 189-193 (2014
10. Yan, H. et al. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 360, 765-773 (2009
11. Hartmann, C. et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1, 010 diffuse gliomas. Acta Neuropathol. 118, 469-474 (2009
12. Liu, X.Y. et al. Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations. Acta Neuropathol. 124, 615-625 (2012
13. Jiao, Y. et al. Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget 3, 709-722 (2012
14. Bettegowda, C. et al. Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science 333, 1453-1455 (2011
15. Killela, P.J. et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc. Natl. Acad. Sci. USA 110, 6021-6026 (2013
16. Kannan, K. et al. Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma. Oncotarget 3, 1194-1203 (2012
17. Arita, H. et al. Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss. Acta Neuropathol. 126, 267-276 (2013
18. Shiraishi, Y. et al. An empirical Bayesian framework for somatic mutation detection from cancer genome sequencing data. Nucleic Acids Res. 41, e89 (2013
19. Sato, Y. et al. Integrated molecular analysis of clear-cell renal cell carcinoma. Nat. Genet. 45, 860-867 (2013
20. Yoshida, K. et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 478, 64-69 (2011
21. Lawrence, M.S. et al. Mutational heterogeneity in cancer and the search for new cancer-Associated genes. Nature 499, 214-218 (2013
22. Cancer Genome Atlas Research Netowrk. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061-1068 (2008
23. Frattini, V. et al. The integrated landscape of driver genomic alterations in glioblastoma. Nat. Genet. 45, 1141-1149 (2013
24. Brennan, C.W. et al. The somatic genomic landscape of glioblastoma. Cell 155, 462-477 (2013
25. Zhang, J. et al. Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat. Genet. 45, 602-612 (2013
26. Jones, D.T. et al. Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat. Genet. 45, 927-932 (2013
27. Okamoto, Y. et al. Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Acta Neuropathol. 108, 49-56 (2004
28. Yip, S. et al. Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers. J. Pathol. 226, 7-16 (2012
29. Watanabe, T., Nobusawa, S., Kleihues, P. & Ohgaki, H. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am. J. Pathol. 174, 1149-1153 (2009
30. Vogazianou, A.P. et al. Distinct patterns of 1p and 19q alterations identify subtypes of human gliomas that have different prognoses. Neuro-oncol. 12, 664-678 (2010
31. Van den Bent, M.J. et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin. Cancer Res. 16, 1597-1604 (2010
32. Wiestler, B. et al. ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. Acta Neuropathol. 126, 443-451 (2013
33. Noushmehr, H. et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17, 510-522 (2010
34. Wiestler, B. et al. Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma. Acta Neuropathol. 128, 561-571 (2014
35. Fontebasso, A.M. et al. Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas. Acta Neuropathol. 125, 659-669 (2013
36. Mantha, S. et al. Activating Notch1 mutations are an early event in T-cell malignancy of Ikaros point mutant Plastic/+ mice. Leuk. Res. 31, 321-327 (2007
37. Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 489, 519-525 (2012
38. Agrawal, N. et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 333, 1154-1157 (2011
39. Weng, A.P. et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 306, 269-271 (2004
40. Dalgliesh, G.L. et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 463, 360-363 (2010
41. Zhu, X. et al. Identification of functional cooperative mutations of SETD2 in human acute leukemia. Nat. Genet. 46, 287-293 (2014
42. Bao, Z.S. et al. RNA-seq of 272 gliomas revealed a novel, recurrent PTPRZ1-MET fusion transcript in secondary glioblastomas. Genome Res. 24, 1765-1773 (2014
43. Di Stefano, A.L. et al. Detection, characterization and inhibition of FGFR-TACC fusions in IDH wild type glioma. Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-14-2199 (21 January 2015
44. Lancaster, J.F. & Quade, D. Random effects in paired-comparison experiments using the Bradley-Terry model. Biometrics 39, 245-249 (1983
45. Ding, L. et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 481, 506-510 (2012
46. Gerlinger, M. et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883-892 (2012
47. Yachida, S. & Iacobuzio-Donahue, C.A. Evolution and dynamics of pancreatic cancer progression. Oncogene 32, 5253-5260 (2013
48. Wang, Y. et al. Clonal evolution in breast cancer revealed by single nucleus genome sequencing. Nature 512, 155-160 (2014
49. Zhang, J. et al. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science 346, 256-259 (2014
50. De Bruin, E.C. et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science 346, 251-256 (2014
51. Hartmann, C. et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol. 120, 707-718 (2010
52. Haferlach, T. et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 28, 241-247 (2014
53. Papaemmanuil, E. et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 122, 3616-3627 quiz 3699 (2013
54. Nannya, Y. et al. A robust algorithm for copy number detection using high-density oligonucleotide single nucleotide polymorphism genotyping arrays. Cancer Res. 65, 6071-6079 (2005
55. Yamamoto, G. et al. Highly sensitive method for genomewide detection of allelic composition in nonpaired, primary tumor specimens by use of Affymetrix single-nucleotide-polymorphism genotyping microarrays. Am. J. Hum. Genet. 81, 114-126 (2007
56. Niida, A., Imoto, S., Shimamura, T. & Miyano, S. Statistical model-based testing to evaluate the recurrence of genomic aberrations. Bioinformatics 28, i115-i120 (2012
57. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545-15550 (2005
58. Shain, A.H. & Pollack, J.R. The spectrum of SWI/SNF mutations, ubiquitous in human cancers. PLoS ONE 8, e55119 (2013
59. Santos-Rosa, H. & Caldas, C. Chromatin modifier enzymes, the histone code and cancer. Eur. J. Cancer 41, 2381-2402 (2005
60. Katagiri, T. et al. Frequent loss of HLA alleles associated with copy number-neutral 6pLOH in acquired aplastic anemia. Blood 118, 6601-6609 (2011
61. Yoshida, K. et al. The landscape of somatic mutations in Down syndrome-related myeloid disorders. Nat. Genet. 45, 1293-1299 (2013
62. Shah, S.P. et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 486, 395-399 (2012
63. Purdom, P.W. Jr., Bradford, P.G., Tamura, K. & Kumar, S. Single column discrepancy and dynamic max-mini optimizations for quickly finding the most parsimonious evolutionary trees. Bioinformatics 16, 140-151 (2000
64. Gerlinger, M. et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat. Genet. 46, 225-233 (2014
65. Tamura, K., Stecher, G., Peterson, D., Filipski, A. & Kumar, S. MEGA6: Molecular Evolutionary Genetics Analysis version 6.0. Mol. Biol. Evol. 30, 2725-2729 (2013